Kitov Product Pipeline
The Kitov pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates that maintain advantages over current therapies or address unmet medical needs.
Our pipeline consists of two therapeutic candidates:
NT-219 – a first-in-class small molecule designed to overcome cancer drug resistance
KIT-302 – a fixed-dose combination of two approved drug products that treats osteoarthritis pain and hypertension simultaneously. A New Drug Application (NDA) was submitted in July 2017 and the U.S. Food and Drug Administration (FDA) filed the NDA on September 29 2017, thereby accepting the NDA for a full review.